Fi­nal AC­TIV-2 en­roll­ment is stopped, leav­ing tiny biotech with­out a sec­ond PhI­II study

The NIH’s AC­TIV-2 tri­al has proved a high­ly suc­cess­ful ef­fort, ex­am­in­ing sev­er­al dif­fer­ent Covid-19 treat­ments in an out­pa­tient set­ting and re­sult­ing in a few EUAs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER